Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Aethlon Medical, Inc. (AEMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5898-0.0308 (-4.96%)
At close: 04:00PM EST
0.5900 +0.00 (+0.03%)
After hours: 07:15PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6206
Open0.6256
Bid0.5821 x 900
Ask0.6200 x 1000
Day's Range0.5781 - 0.6500
52 Week Range0.2300 - 2.4600
Volume219,395
Avg. Volume1,113,159
Market Cap13.534M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.7060
Earnings DateFeb 13, 2023 - Feb 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023

    Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET. Steven LaRosa, M.D., Chief Medical Officer and Chief Scientific Officer of Aethlon Medical, will be giving the presentation.

  • PR Newswire

    Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer

    Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious diseases, today announced that it has entered into an agreement with NAMSA, a world leading MedTech Contract Research Organization (CRO) offering global end-to-end development services to oversee the company's clinical trials investigating the Hemopurifier, Aethlon's immunotherapeutic device , for oncology indications.

  • Zacks Small Cap Research

    AEMD: Hemopurifier Hemopurifier To Be Studied in a Variety of Solid Tumors

    By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Studying the Hemopurifier in a range of cancers Aethlon Medical’s (NASDAQ:AEMD) provided a business update. AEMD has been working to launch a blanket oncology trial to study the impact of the Hemopurifier on a variety of cancerous tumors. The company’s goal is to build its database in oncology to help with the development of the

Advertisement
Advertisement